Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.
ACS Cent Sci
; 7(4): 650-657, 2021 Apr 28.
Article
in English
| MEDLINE | ID: covidwho-1225484
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Severe cases of coronavirus disease 2019 (COVID-19), caused by infection with SARS-CoV-2, are characterized by a hyperinflammatory immune response that leads to numerous complications. Production of proinflammatory neutrophil extracellular traps (NETs) has been suggested to be a key factor in inducing a hyperinflammatory signaling cascade, allegedly causing both pulmonary tissue damage and peripheral inflammation. Accordingly, therapeutic blockage of neutrophil activation and NETosis, the cell death pathway accompanying NET formation, could limit respiratory damage and death from severe COVID-19. Here, we demonstrate that synthetic glycopolymers that activate signaling of the neutrophil checkpoint receptor Siglec-9 suppress NETosis induced by agonists of viral toll-like receptors (TLRs) and plasma from patients with severe COVID-19. Thus, Siglec-9 agonism is a promising therapeutic strategy to curb neutrophilic hyperinflammation in COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal:
ACS Cent Sci
Year:
2021
Document Type:
Article
Affiliation country:
Acscentsci.0c01669
Similar
MEDLINE
...
LILACS
LIS